Multiplex Assays Market: By Products and
Services (Consumables, Instruments), by Types (Protein & Nucleic Acid
Assay), by Technology (Flow Cytometry & Other Technology), by Application
(Clinical Diagnostic), & End-User (Hospital)– Forecast Till 2023
Multiplex
Assays Market Size – Overview
The
uptick in demand for nanotechnology
practices that can solve several genetic-related
diseases has increased of late. The Multiplex
Assays Market Size is anticipated to progress with a CAGR of 7.8% during
the forecast period. The market for multiplex arrays is advancing due to the
increased funding and research being diverted
to the market. Increased awareness of the benefits of multiplex assays is
fuelling the growth of the market over the forecast period. The multifactorial
nature of several diseases and pathological conditions such as Alzheimer and
cancer are motivating the development of the market significantly.
Segmental Analysis
The multiplex assay market is segmented on the basis of
types, application, products and services, technology, and end-user. By products and services, the market is segmented into instrument, consumable, and
software and services. Based on types, the market is segmented into nucleic
acid, protein, and cell-based multiplex assay. On
the basis of technology, the market is segmented into fluorescence
detection, flow cytometry, luminescence, multiplex
real-time PCR, and other technologies. On
the basis of application, the market is segmented into clinical
diagnostic, research and development, and other diseases. By end user, the market is segmented into
hospital and research institutes, pharmaceutical and biotechnology companies,
clinical laboratories, and other end-users.
Competitive
Analysis
The availability of a good labor force along with assets is
influencing to the general market advancement. The external factors that are
motivating the market expansion which is dependent on the practices and the
strategic roadmaps that are exploited by market players. The
alteration in the quality of products and services is the chief factor is growing the market's output and swaying the trends that are fortifying their
prominence in the market. The essential success factors and players’
inclinations are progressively improving by the strategies being used by market competitors. The market
has brought in an innovative period of growth as the market is constantly in a
state of mutability.
The
notable contenders shaping the market development over the forecast period are
Illumina Inc, Bio Rad Laboratories Inc, Thermo Fisher Scientific Inc, Qiagen, Abcam plc, BD, Agilent Technologies,
Meso Scale Diagnostics LLC, Merck Sharp & Dohme Corp, Quanterix,
Bio-Techne, Randox Laboratories Ltd, and Seegene Inc.
Industry Updates:
Jun 2018
Laboratory Corporation of America announced of late that it has gotten US Food and Drug Administration consent
for the UltraQual Multiplex PCR Assay for HIV-1, hepatitis C, HIV-2 and
hepatitis B for the diagnosing of donated blood plasma.
Detailed Regional
Analysis
The North America region is accountable for the prime stake of
the market due to robust R&D activities in this region. The US is a chief
country in terms of biopharmaceutical
research and development. The important factors that drive the development of
the market in this region are the rise in-patient
population, and the growing detection of Alzheimer disease, and a substantial
rise in research and development activities of the pharmaceutical companies for
the treatment of diseases such as cancer and Alzheimer. The Asia Pacific is
anticipated to record the highest CAGR during the forecast period. Due to the increasing geriatric population, mounting
prevalence of cataract, and growing prevalence of Alzheimer disease in
this region. The European region is estimated to note a high CAGR during the
forecast period owing to the increasing geriatric population.
No comments:
Post a Comment